Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the emerging therapeutic efficacy of CAR-T cell therapies for patients with multiple myeloma. Given the demonstrated efficacy of quadruplet induction regimens, Dr Giralt highlights that cellular therapies should be employed in combination, and will hopefully result in long-term remissions and improved patient outcomes. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть